TG THERAPEUTICS, INC. (TGTX) FY2025 10-K Annual Report
TG THERAPEUTICS, INC. (TGTX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
TG THERAPEUTICS, INC. FY2025 10-K Analysis
Business Overview
- • Core business: Fully integrated biotech focused on novel treatments for B-cell diseases, principally commercializing BRIUMVI for relapsing multiple sclerosis (RMS)
- • New initiatives: Launched Next In MS™ awareness platform with Christina Applegate; initiated Phase 3 enrollment for subcutaneous ublituximab; dosed first patient with azer-cel CAR T therapy in Phase 1 for progressive MS
- • Strategic shift: Expansion of BRIUMVI commercialization into Europe via $140M upfront deal with Neuraxpharm; emphasis on dosing schedule simplification and subcutaneous formulation development
- • Notable metric: Completed $100M share repurchase, acquiring 3.5 million shares at $28.55 average; Phase 3 subcutaneous ublituximab trial over 75% enrolled as of Feb 2026
- • Unique fact: Presented six-year data from ULTIMATE I & II trials showing 89.9% patients free from confirmed disability progression and ARR of 0.012, indicating sustained long-term efficacy and safety
Management Discussion & Analysis
- • No revenue or profitability data provided in the excerpt
- • No segment performance or cash flow information disclosed
- • No capital allocation details such as buybacks, dividends, or capex mentioned
- • Forward-looking statements include general caution on risks and uncertainties
- • No specific management guidance or outlook included in the provided text
Risk Factors
- • Cybersecurity breach risk impacting drug candidate development and commercialization via failures in internal or third-party CROs, CMOs, or contractors
- • Management oversight of cybersecurity risks with Board receiving regular reports on material threats and IT security effectiveness
- • Vice President of IT responsible for cybersecurity risk management, holds multiple certifications, with 25+ years experience
TG THERAPEUTICS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$616M
▲ +87.3% YoY
Net Income
$447M
▲ +1812.4% YoY
Operating Margin
20.0%
▲ +727bp YoY
Net Margin
72.6%
▲ +6545bp YoY
ROE
69.0%
▲ +5849bp YoY
Total Assets
$1.1B
▲ +84.1% YoY
EPS (Diluted)
$2.77
▲ +1746.7% YoY
Operating Cash Flow
-$25M
▲ +38.9% YoY
Source: XBRL data from TG THERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TG THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.